# US 2012/0251541 A1 · Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251541 A1
- Document ID: US20120251541A1
- Status: Published application
- Kind: A1
- Application number: 13/433,033
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-28
- Assignees: Sanofi
- Inventors: Nicolas Baurin; Christian Beil; Carsten Corvey; Christian Lange; Danxi Li; Vincent Mikol; Anke Steinmetz; Ercole Rao
- Web page: https://patentgrep.com/patent/US20120251541A1

## CPC

- A61P 37/02: Immunomodulators
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/245: {IL-1}
- C07K 16/247: {IL-4}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/461: {Igs containing Ig-regions, -domains or -residues form different species}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 16/32: against translation products of oncogenes
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/53: Hinge
- C07K 2317/55: Fab or Fab'
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/66: comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2318/00: Antibody mimetics or scaffolds
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

## Claims

### Claim 1

An antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, wherein two polypeptide chains have a structure represented by the formula:
VL1-L1-VL2-L2-CL [I]
and two polypeptide chains have a structure represented by the formula:
VH2-L3-VH1-L4-CH1-Fc [II]
wherein:
VL1 is a first immunoglobulin light chain variable domain;
VL2 is a second immunoglobulin light chain variable domain;
VH1 is a first immunoglobulin heavy chain variable domain;
VH2 is a second immunoglobulin heavy chain variable domain;
CL is an immunoglobulin light chain constant domain;
CH1 is the immunoglobulin CH1 heavy chain constant domain;
Fc is the immunoglobulin hinge region and CH2, CH3 immunoglobulin heavy chain constant domains; and
L1, L2, L3, and L4 are amino acid linkers;
and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

### Claim 2 (depends on 1)

The antibody-like binding protein of claim 1, wherein:
L1 is 3 to 12 amino acid residues in length;
L2 is 3 to 14 amino acid residues in length;
L3 is 1 to 8 amino acid residues in length; and
L4 is 1 to 3 amino acid residues in length.

### Claim 3 (depends on 2)

The antibody-like binding protein of claim 2, wherein:
L1 is 5 to 10 amino acid residues in length;
L2 is 5 to 8 amino acid residues in length;
L3 is 1 to 5 amino acid residues in length; and
L4 is 1 to 2 amino acid residues in length.

### Claim 4 (depends on 3)

The antibody-like binding protein of claim 3, wherein:
L1 is 7 amino acid residues in length;
L2 is 5 amino acid residues in length;
L3 is 1 amino acid residues in length; and
L4 is 2 amino acid residues in length.

### Claim 5 (depends on 1)

The antibody-like binding protein of claim 1, wherein:
L1 is 1 to 3 amino acid residues in length;
L2 is 1 to 4 amino acid residues in length;
L3 is 2 to 15 amino acid residues in length; and
L4 is 2 to 15 amino acid residues in length.

### Claim 6 (depends on 5)

The antibody-like binding protein of claim 5, wherein:
L1 is 1 to 2 amino acid residues in length;
L2 is 1 to 2 amino acid residues in length;
L3 is 4 to 12 amino acid residues in length; and
L4 is 2 to 12 amino acid residues in length.

### Claim 7 (depends on 6)

The antibody-like binding protein of claim 6, wherein:
L1 is 1 amino acid residue in length;
L2 is 2 amino acid residues in length;
L3 is 7 amino acid residues in length; and
L4 is 5 amino acid residues in length.

### Claim 8 (depends on 1)

The antibody-like binding protein of claim 1, wherein L1 is 0 amino acid residues in length and L3 is 2 or more amino acid residues in length.

### Claim 9 (depends on 1)

The antibody-like binding protein of claim 1, wherein L3 is 0 amino acid residues in length and L1 is 1 or more amino acid residues in length.

### Claim 10 (depends on 1)

The antibody-like binding protein of claim 1, wherein L4 is 0 amino acid residues in length and L2 is 3 or more amino acid residues in length.

### Claim 11 (depends on 1)

The antibody-like binding protein of claim 1, wherein the binding protein is capable of specifically binding one or more antigen targets.

### Claim 12 (depends on 11)

The antibody-like binding protein of claim 11, wherein the one or more antigen targets is selected from the group consisting of B7.1, B7.2, BAFF, BlyS, C3, C5, CCL11 (eotaxin), CCL15 (MIP-1d), CCL17 (TARC), CCL19 (MIP-3b), CCL2 (MCP-1), CCL20 (MIP-3a), CCL21 (MIP-2), SLC, CCL24 (MPIF-2/eotaxin-2), CCL25 (TECK), CCL26 (eotaxin-3), CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CD3, CD19, CD20, CD24, CD40, CD40L, CD80, CD86, CDH1 (E-cadherin), Chitinase, CSF1 (M-CSF), CSF2 (GM-CSF), CSF3 (GCSF), CTLA4, CX3CL1 (SCYD1), CXCL12 (SDF1), CXCL13, EGFR, FCER1A, FCER2, HER2, IGF1R, IL-1, IL-12, IL13, IL15, IL17, IL18, IL1A, IL1B, IL1F10, IL1β, IL2, IL4, IL6, IL7, IL8, IL9, IL12/23, IL22, IL23, IL25, IL27, IL35, ITGB4 (b 4 integrin), LEP (leptin), MHC class II, TLR2, TLR4, TLR5, TNF, TNFα, TNFSF4 (OX40 ligand), TNFSF5 (CD40 ligand), Toll-like receptors, TREM1, TSLP, TWEAK, XCR1 (GPR5/CCXCR1), DNGR-1 (CLEC91), and HMGB1.

### Claim 13 (depends on 1)

The antibody-like binding protein of claim 1, wherein the binding protein is bispecific and capable of binding two different antigen targets.

### Claim 14 (depends on 13)

The antibody-like binding protein of claim 13, wherein the two different antigen targets are selected from the group consisting of IL4 and IL13, IGF1R and HER2, IGF1R and EGFR, EGFR and HER2, BK and IL13, PDL-1 and CTLA-4, CTLA4 and MHC class II, IL-12 and IL-18, IL-1α and IL-1β, TNFα and IL12/23, TNFα and IL-12p40, TNFα and IL1β, TNFα and IL-23, and IL17 and IL23.

### Claim 15 (depends on 1)

The antibody-like binding protein of claim 1, wherein the binding protein is capable of inhibiting the function of one or more of the antigen targets.

### Claim 16 (depends on 1)

The antibody-like binding protein of claim 1, wherein at least one of the linkers selected from the group consisting of L1, L2, L3, and L4 contains at least one cysteine residue.

### Claim 17

An antibody-like binding protein comprising two polypeptide chains that form two antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:
VL1-L1-VL2-L2-CL [I]
and a second polypeptide chain has a structure represented by the formula:
VH2-L3-VH1-L4-CH1 [II]
wherein:
VL1 is a first immunoglobulin light chain variable domain;
VL2 is a second immunoglobulin light chain variable domain;
VH1 is a first immunoglobulin heavy chain variable domain;
VH2 is a second immunoglobulin heavy chain variable domain;
CL is an immunoglobulin light chain constant domain;
CH1 is the immunoglobulin CH1 heavy chain constant domain; and
L1, L2, L3, and L4 are amino acid linkers;
and wherein the first and second polypeptides form a cross-over light chain-heavy chain pair.

### Claim 18 (depends on 17)

The antibody-like binding protein of claim 17, wherein:
L1 is 3 to 12 amino acid residues in length;
L2 is 3 to 14 amino acid residues in length;
L3 is 1 to 8 amino acid residues in length; and
L4 is 1 to 3 amino acid residues in length.

### Claim 19 (depends on 18)

The antibody-like binding protein of claim 18, wherein:
L1 is 5 to 10 amino acid residues in length;
L2 is 5 to 8 amino acid residues in length;
L3 is 1 to 5 amino acid residues in length; and
L4 is 1 to 2 amino acid residues in length.

### Claim 20 (depends on 19)

The antibody-like binding protein of claim 19, wherein:
L1 is 7 amino acid residues in length;
L2 is 5 amino acid residues in length;
L3 is 1 amino acid residues in length; and
L4 is 2 amino acid residue in length.

### Claim 21 (depends on 17)

The antibody-like binding protein of claim 17, wherein:
L1 is 1 to 3 amino acid residues in length;
L2 is 1 to 4 amino acid residues in length;
L3 is 2 to 15 amino acid residues in length; and
L4 is 2 to 15 amino acid residues in length.

### Claim 22 (depends on 21)

The antibody-like binding protein of claim 21, wherein:
L1 is 1 to 2 amino acid residues in length;
L2 is 1 to 2 amino acid residues in length;
L3 is 4 to 12 amino acid residues in length; and
L4 is 2 to 12 amino acid residues in length.

### Claim 23 (depends on 22)

The antibody-like binding protein of claim 22, wherein:
L1 is 1 amino acid residue in length;
L2 is 2 amino acid residues in length;
L3 is 7 amino acid residues in length; and
L4 is 5 amino acid residues in length.

### Claim 24 (depends on 17)

The antibody-like binding protein of claim 17, wherein L1 is 0 amino acid residues in length and L3 is 2 or more amino acid residues in length.

### Claim 25 (depends on 17)

The antibody-like binding protein of claim 17, wherein L3 is 0 amino acid residues in length and L1 is 1 or more amino acid residues in length.

### Claim 26 (depends on 17)

The antibody-like binding protein of claim 17, wherein L4 is 0 amino acid residues in length and L2 is 3 or more amino acid residues in length.

### Claim 27 (depends on 17)

The antibody-like binding protein of claim 17, wherein the binding protein is capable of specifically binding one or more antigen targets.

### Claim 28 (depends on 27)

The antibody-like binding protein of claim 27, wherein the one or more antigen targets is selected from the group consisting of B7.1, B7.2, BAFF, BlyS, C3, C5, CCL11 (eotaxin), CCL15 (MIP-1d), CCL17 (TARC), CCL19 (MIP-3b), CCL2 (MCP-1), CCL20 (MIP-3a), CCL21 (MIP-2), SLC, CCL24 (MPIF-2/eotaxin-2), CCL25 (TECK), CCL26 (eotaxin-3), CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CD3, CD19, CD20, CD24, CD40, CD40L, CD80, CD86, CDH1 (E-cadherin), Chitinase, CSF1 (M-CSF), CSF2 (GM-CSF), CSF3 (GCSF), CTLA4, CX3CL1 (SCYD1), CXCL12 (SDF1), CXCL13, EGFR, FCER1A, FCER2, HER2, IGF1R, IL-1, IL-12, IL13, IL15, IL17, IL18, IL1A, IL1B, IL1F10, IL1β, IL2, IL4, IL6, IL7, IL8, IL9, IL12/23, IL22, IL23, IL25, IL27, IL35, ITGB4 (b 4 integrin), LEP (leptin), MHC class II, TLR2, TLR4, TLR5, TNF, TNFα, TNFSF4 (OX40 ligand), TNFSF5 (CD40 ligand), Toll-like receptors, TREM1, TSLP, TWEAK, XCR1 (GPR5/CCXCR1), DNGR-1 (CLEC91), and HMGB1.

### Claim 29 (depends on 17)

The antibody-like binding protein of claim 17, wherein the binding protein is bispecific and capable of binding two different antigen targets.

### Claim 30 (depends on 29)

The antibody-like binding protein of claim 29, wherein the two different antigen targets are selected from the group consisting of IL4 and IL13, IGF1R and HER2, IGF1R and EGFR, EGFR and HER2, BK and IL13, PDL-1 and CTLA-4, CTLA4 and MHC class II, IL-12 and IL-18, IL-1α and IL-β, TNFα and IL12/23, TNFα and IL-12p40, TNFα and IL1β, TNFα and IL-23, and IL17 and IL23.

### Claim 31 (depends on 17)

The antibody-like binding protein of claim 17, wherein the binding protein is capable of inhibiting the function of one or more of the antigen targets.

### Claim 32 (depends on 17)

The antibody-like binding protein of claim 17, wherein at least one of the linkers selected from the group consisting of L1, L2, L3, and L4 contains at least one cysteine residue.

### Claim 33 (depends on 1, 17)

An isolated nucleic acid molecule comprising a nucleotide sequence encoding the antibody-like binding protein of either claim 1 or 17.

### Claim 34 (depends on 33)

An expression vector comprising the nucleic acid molecule of claim 33.

### Claim 35 (depends on 33)

An isolated host cell comprising the nucleic acid molecule of claim 33.

### Claim 36 (depends on 34)

An isolated host cell comprising the expression vector of claim 34.

### Claim 37 (depends on 35, 36)

The host cell of either claim 35 or 36, wherein the host cell is a mammalian cell or an insect cell.

### Claim 38 (depends on 1, 17)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody-like binding protein of either claim 1 or 17.

### Claim 39 (depends on 1)

A method for making the antibody-like binding protein of claim 1, comprising expressing in a cell one or more nucleic acid molecules encoding polypeptides having structures represented by the formulas [I] and [II] below:
VL1-L1-VL2-L2-CL [I]
VH2-L3-VH1-L4-CH1-Fc [II]
wherein:
VL1 is a first immunoglobulin light chain variable domain;
VL2 is a second immunoglobulin light chain variable domain;
VH1 is a first immunoglobulin heavy chain variable domain;
VH2 is a second immunoglobulin heavy chain variable domain;
CL is an immunoglobulin light chain constant domain;
CH1 is the immunoglobulin CH1 heavy chain constant domain;
Fc is the immunoglobulin hinge region and CH2, CH3 immunoglobulin heavy chain constant domains; and
L1, L2, L3, and L4 are amino acid linkers;
and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

### Claim 40 (depends on 17)

A method for making the antibody-like binding protein of claim 17, comprising expressing in a cell one or more nucleic acid molecules encoding polypeptides having structures represented by the formulas [I] and [II] below:
VL1-L1-VL2-L2-CL [I]
VH2-L3-VH1-L4-CH1 [II]
wherein:
VL1 is a first immunoglobulin light chain variable domain;
VL2 is a second immunoglobulin light chain variable domain;
VH1 is a first immunoglobulin heavy chain variable domain;
VH2 is a second immunoglobulin heavy chain variable domain;
CL is an immunoglobulin light chain constant domain;
CH1 is the immunoglobulin CH1 heavy chain constant domain; and
L1, L2, L3, and L4 are amino acid linkers;
and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

### Claim 41

A method of making an antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, comprising:
(a) identifying a first antibody variable domain that binds a first target antigen and a second antibody variable domain that binds a second target antigen, each containing a VL, and a VH;
(b) assigning either the light chain or the heavy chain as template chain;
(c) assigning the VL of the first antibody variable domain or the second antibody variable domain as VL1;
(d) assigning a VL2; a VH1, and a VH2 according to formulas [I] and [II] below:
VL1-L1-VL2-L2-CL [I]
VH2-L3-VH1-L4-CH1-Fc [II]
(e) determining maximum and minimum lengths for L1, L2, L3, and L4;
(f) generating polypeptide structures of formulas I and II;
(g) selecting polypeptide structures of formulas I and II that bind the first target antigen and the second target antigen when combined to form the antibody-like binding protein;
wherein:
VL1 is a first immunoglobulin light chain variable domain;
VL2 is a second immunoglobulin light chain variable domain;
VH1 is a first immunoglobulin heavy chain variable domain;
VH2 is a second immunoglobulin heavy chain variable domain;
CL is an immunoglobulin light chain constant domain;
CH1 is the immunoglobulin CH1 heavy chain constant domain;
Fc is the immunoglobulin hinge region and CH2, CH3 immunoglobulin heavy chain constant domains; and
L1, L2, L3, and L4 are amino acid linkers;
and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

### Claim 42 (depends on 41)

The method of claim 41, wherein the first antibody variable domain and the second antibody variable domain are the same.

### Claim 43

A method of making an antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, comprising:
(a) identifying a first antibody variable domain that binds a first target antigen and a second antibody variable domain that binds a second target antigen, each containing a VL, and a VH;
(b) assigning either the light chain or the heavy chain as template chain;
(c) assigning the VL of the first antibody variable domain or the second antibody variable domain as VL1;
(d) assigning a VL2; a VH1, and a VH2 according to formulas [I] and [II] below:
VL1-L1-VL2-L2-CL [I]
VH2-L3-VH1-L4-CH1 [II]
(e) determining maximum and minimum lengths for L1, L2, L3, and L4;
(f) generating polypeptide structures of formulas I and II;
(g) selecting polypeptide structures of formulas I and II that bind the first target antigen and the second target antigen when combined to form the antibody-like binding protein;
wherein:
VL1 is a first immunoglobulin light chain variable domain;
VL2 is a second immunoglobulin light chain variable domain;
VH1 is a first immunoglobulin heavy chain variable domain;
VH2 is a second immunoglobulin heavy chain variable domain;
CL is an immunoglobulin light chain constant domain;
CH1 is the immunoglobulin CH1 heavy chain constant domain; and
L1, L2, L3, and L4 are amino acid linkers;
and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

### Claim 43 (depends on 44)

The method of claim 44, wherein the first antibody variable domain and the second antibody variable domain are the same.
